IC
RCKT icon

Ikarian Capital’s Rocket Pharmaceuticals RCKT Stock Holding History

Ikarian Capital’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-150,000
Closed -$4.5M – 174
2023
Q4 		$4.5M Buy
150,000
+148,500
+9,900% +$3.28M 0.42% 62
2023
Q3 		$3.07M Buy
+1,500
New +$27.3K 0.37% 66

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Ikarian Capital's RCKT Position: Q2 2025 in Review

Ikarian Capital sold out of Rocket Pharmaceuticals (RCKT) in Q2 2025, closing a stake of 221,911 shares — an estimated $1.48M sold.

Ikarian Capital first reported a position in RCKT in Q4 2020 and held it in 9 quarters. The position peaked at $13.4M in Q3 2023. 196 funds tracked by Wall St. Rank hold RCKT as of Q2 2025.

  • Ikarian Capital reported no remaining Rocket Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Ikarian Capital sold 221,911 Rocket Pharmaceuticals shares in Q2 2025, an estimated $1.48M.
  • Ikarian Capital first reported a position in Rocket Pharmaceuticals in Q4 2020 and held it in 9 quarters.
  • Ikarian Capital's Rocket Pharmaceuticals position peaked at $13.4M in Q3 2023.
  • 196 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2025.

Based on Ikarian Capital's 13F filing for Q2 2025, filed 14 Aug 2025.